OncologyTube Professional - Patients Click Here
250,107 video views
Loading........
Description: Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains how the landscape is changing in treating metastatic hormone-sensitive prostate cancer.
01:16
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains how the landscape is changing in treating metastatic hormone-sensiti​ve prostate cancer.
by:obr | 368 views
01:27
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the anticipated trial results involving I-O, TKIs and biomarkers in renal cell carcinoma (RCC).
by:obr | 68 views
01:21
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, discusses strategies for the 2nd line renal cell carcinoma (RCC) patients following I-O.
by:obr | 56 views
01:20
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, provides perspective on treating newly diagnosed renal cell carcinoma (RCC) patients.
by:obr | 85 views
02:37
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the studies and outcomes in sarcomatoid renal cell cancer and urothelial cancer.
by:obr | 58 views
02:12
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the design on the outcomes of the PDIGREE trial in metastatic, untreated renal cell carcinoma.
by:obr | 24 views
02:48
Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atriu​m Health, UNC Chapel Hill School of Medicine shares the data in smoldering multiple myeloma (MM) presented at ASCO 2019.
by:obr | 66 views
01:53
Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atriu​m Health, UNC Chapel Hill School of Medicine provides outcomes from the MAIA study that compares daratumumab + lenalidomide + dexamethasone versus lenalidomide + dexamethasone in multiple myeloma elderly patients.
by:obr | 155 views
01:38
Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atriu​m Health, UNC Chapel Hill School of Medicine, compares intravenous daratumumab versus subcutaneous daratumumab.
by:obr | 43 views
01:55
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center explains the results of the SOPHIA trial, a phase III study of chemotherapy plus margetuximab or trastuzumab in HER+ metastatic breast cancer.
by:obr | 29 views

About obr
Description: OBR is the most comprehensive digital platform for oncology focused news and information: We aggregate, customize and prioritize daily oncology news and publications (OBR Daily for industry and providers, RSS newsfeeds) We research, develop and publish original content (OBR green) We create and produce customized training programs for pharmaceutical professionals (Oncology Business Dynamics) We conduct, interpret, analyze and produce original research (On-Telligence) We publish informational resources and editorial perspective to our websites (OBR Radar, Pipeline Online, Blog, Twitter, OBR Finance, News Pulse, KOL Commentary, and others)

Links
Channel Url:

Website:


Social Links: